Featured Press Releases

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis

Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis

  • 06 Jun 2024

Agomab Therapeutics NV (‘Agomab’) announced that it has received Orphan Drug Designation from the...

GoodRx debuts a new e-commerce platform, starting with Opill®

GoodRx debuts a new e-commerce platform, starting with Opill®

Doer Biologics announces the dosing of the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia treatment.

Doer Biologics announces the dosing of the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia treatment.

2025 Interim Results and Business Updates Announced by Innovent

2025 Interim Results and Business Updates Announced by Innovent

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

Voranigo® (vorasidenib) from Servier has received multiple regional Prix Galien Awards

Voranigo® (vorasidenib) from Servier has received multiple regional Prix Galien Awards

  • Servier
  • 09 Dec 2025
FIZE Medical, in an exclusive deal with Asahi Kasei Medical, has launched the FIZE kUO® System in Japan

FIZE Medical, in an exclusive deal with Asahi Kasei Medical, has launched the FIZE kUO® System in Japan

  • FIZE Medical
  • 09 Dec 2025
GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

  • Erbe Elektromedizin GmbH
  • 03 Dec 2025
Within one year of its launch, L&C Bio

Within one year of its launch, L&C Bio's 'Re2O' has emerged as a leading procedure in K-Medical Tourism

  • L&C BIO Co., Ltd
  • 03 Dec 2025
Health Canada has granted Celltrion approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg).

Health Canada has granted Celltrion approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg).

  • Celltrion
  • 01 Dec 2025
Samsung Bioepis Announces the Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe

Samsung Bioepis Announces the Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe

  • Samsung Bioepis Co., Ltd.
  • 01 Dec 2025
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
December   2025
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.